Physician profile
Nancy S Harrison
NPI 1457763336
$15,892.53
in general payments reported to CMS, 2019-2025
29 companies · $2,977 in 2025
The $2,977 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $1,330 · 2021: $2,352 · 2022: $2,172 · 2023: $2,473 · 2024: $3,076 · 2025: $2,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,510 · Education: $16.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,510.11 |
| Education | $16.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,329.43 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $3,056.05 | 2019-2025 | |
| Ucb, INC. | $1,285.16 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,004.35 | 2020-2025 | |
| Janssen Biotech, INC. | $864.62 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $846.13 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $606.49 | 2022-2025 | Saphnelo, Evusheld |
| Genentech USA, INC. | $589.41 | 2019-2025 | Actemra, Gazyva |
| Pfizer INC. | $560.41 | 2019-2025 | |
| Octapharma USA, INC. | $376.46 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Radius Health, INC. | $292.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $261.34 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.65 | 2022-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $245.91 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $243.20 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $242.49 | 2023-2025 | Idacio |
| Lilly USA, LLC | $191.40 | 2020-2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $144.42 | 2019 | |
| Ani Pharmaceuticals, INC. | $102.80 | 2024-2025 | Purified Cortrophin Gel |
| Sobi, INC | $95.16 | 2022-2025 | |
| Horizon Therapeutics Plc | $88.05 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $65.81 | 2022-2025 | Acthar |
| Tonix Medicines, INC. | $28.35 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals International, Plc | $27.57 | 2024 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $27.41 | 2025 | Strensiq |
| Celgene Corporation | $22.74 | 2019 | |
| Celltrion USA INC. | $16.86 | 2023 | Yuflyma |
| Sandoz INC. | $16.25 | 2025 | Jubbonti |
| Abbott Laboratories | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.